Supernus Pharmaceuticals SUPN Accrued R&D expenses
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept supn:AccruedResearchAndDevelopmentExpensesCurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's accrued r&d expenses.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's accrued r&d expenses?
- Supernus Pharmaceuticals (SUPN) reported accrued r&d expenses of $3.77M in Q1 2026.
- How has Supernus Pharmaceuticals's accrued r&d expenses changed year-over-year?
- Supernus Pharmaceuticals's accrued r&d expenses decreased by 30.3% year-over-year, from $5.41M to $3.77M.
- What is the long-term trend for Supernus Pharmaceuticals's accrued r&d expenses?
- Over 3 years (2022 to 2025), Supernus Pharmaceuticals's accrued r&d expenses has grown at a -0.9% compound annual growth rate (CAGR), from $7.49M to $7.3M.